secwatch.observer — SEC 8-K summary
======================================

Issuer:     aTYR PHARMA INC (ATYR)
CIK:        0001339970
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0000950170-22-024480
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

aTyr Pharma reports Q3 2022 cash $79.6M; Phase 3 sarcoidosis study initiated
----------------------------------------------------------------------------

- Ended Q3 2022 with $79.6M in cash, restricted cash, cash equivalents and investments.
- First patient dosed in EFZO-FIT Phase 3 study of efzofitimod for pulmonary sarcoidosis; targets 264 subjects.
- Will not initiate Phase 1 for ATYR2810 this year; pursuing external non-dilutive funding.
- FDA granted Fast Track designation for efzofitimod in systemic sclerosis-associated ILD.
- Q3 R&D expenses $9.9M, G&A $3.6M; 29.0M shares outstanding.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1339970/000095017022024480/0000950170-22-024480-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1339970/000095017022024480/life-20221110.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-024480

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer